Carregando…
Nanoviricides Inc
Como a empresa evoluiu, ano a ano. Receita e dívida vêm dos relatórios anuais — na maioria das empresas, os 10-K entregues à SEC desde 2009; os dividendos, dos próprios pagamentos.
As barras são um saldo na data de fechamento; as linhas são o que aconteceu ao longo do ano. Receita acima do patrimônio é o normal, não anomalia — significa que a empresa gira o capital mais de uma vez por ano.
Grandes gestores que reportaram esta ação no 13F mais recente.
▼ -69.6% em 5A.
hoje você teria $310.34▼ -69.0%
Com dividendos reinvestidos e desdobramentos considerados. Preço passado diz o que aconteceu, não o que vai acontecer.
Os últimos 20 anos fechados. Cada múltiplo usa o preço de fechamento daquele ano e os números reportados naquele ano — não os de hoje. O alcance é o dos relatórios anuais que temos.
| Indicador | Mediana | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preço no fim do ano | $1.13 | $1.43 | $1.02 | $1.11 | $3.72 | $2.87 | $2.51 | $4.00 | $17.60 | $21.40 | $23.60 | $54.40 | $96.00 | $32.90 |
Empresas de tamanho parecido em Healthcare, para comparar. As colunas são as mesmas de cima, na mesma ordem.
| Ação | Preço | P/L | P/VP | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ATNMActinium Pharmaceuticals, Inc. | $1.01 | 2.9x | 1.0x | — | 45.86% | $31.69M |
| SCLXScilex Holding Co | $4.49 | — | — | — | — | $31.59M |
| MIRAMIRA Pharmaceuticals Inc | $0.75 | — | 3.9x | — | -217.12% | $31.52M |
| TELATELA Bio, Inc. | $0.70 |
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Descrição da empresa fornecida pelo Yahoo Finance. A descrição é publicada pela fonte apenas em inglês.
| $43.40 |
| $102.90 |
| $59.50 |
| $56.70 |
| $27.30 |
| $51.80 |
| P/VP | 2.4x | 2.6x | 1.8x | 0.8x | 0.6x | 1.4x | — | 0.9x | 0.8x | 2.7x | 2.7x | 2.1x | 6.6x | 30.0x | 5.3x | 8.8x | — | — | — | — | — |
| EPS | -$0.63 | -$0.70 | -$0.74 | -$0.70 | -$0.81 | -$2.39 | -$2.35 | -$2.60 | -$3.40 | -$3.80 | -$1.80 | -$5.40 | -$3.80 | -$3.00 | -$3.20 | -$2.80 | — | — | — | — |
| ROE | -62.74% | -125.93% | -72.35% | -57.77% | -35.12% | -29.49% | -61.80% | -79.47% | -48.48% | -50.71% | -46.53% | -6.92% | -58.20% | -110.81% | -44.82% | -63.68% | -72.78% | -112.16% | -617.11% | -623.37% | -265.20% |
Mediana, e não média: um único ano de lucro quase zero dá P/L de 400 e arrastaria a média sozinho. Anos com P/L acima de 200x ficam de fora, o mesmo corte do preço justo — por isso esta mediana bate com o método “histórico da própria empresa” abaixo. Preço e LPA não têm mediana: são séries que crescem.
| — |
| — |
| — |
| — |
| $31.43M |
| IGCIGC Pharma, Inc. | $0.31 | — | 5.2x | — | -83.34% | $32.05M |
| CCELCryo Cell International Inc | $4.00 | — | — | 15.00% | — | $32.25M |